Loading…
Dendritic Cells Transduced with Full-Length Wild-Type p53 Generate Antitumor Cytotoxic T Lymphocytes from Peripheral Blood of Cancer Patients
Accumulation of wild-type or mutant p53 protein occurs in ∼50% of human malignancies. This overexpression may generate antigenic epitopes recognized by CTLs. Because normal cells have undetectable levels of p53, these CTLs are likely to be tumor specific. Here, for the first time, we test the hypoth...
Saved in:
Published in: | Clinical cancer research 2001-01, Vol.7 (1), p.127-135 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Accumulation of wild-type or mutant p53 protein occurs in ∼50% of
human malignancies. This overexpression may generate antigenic epitopes
recognized by CTLs. Because normal cells have undetectable levels of
p53, these CTLs are likely to be tumor specific. Here, for the first
time, we test the hypothesis that full-length wild-type p53 protein can
be used for generation of an immune response against tumor cells with
p53 overexpression. T cells obtained from nine HLA-A2-positive cancer
patients and three HLA-A2-positive healthy individuals were stimulated
twice with dendritic cells (DCs) transduced with an adenovirus
wild-type p53 (Ad-p53) construct. Significant cytotoxicity was detected
against HLA-A2-positive tumor cells with accumulation of mutant or
wild-type p53 but not against HLA-A2-positive tumor cells with normal
(undetectable) levels of p53 or against HLA-A2-negative tumor cells.
This response was specific and mediated by CD8 + CTLs. These
CTLs recognized HLA-A2-positive tumor cells expressing normal levels of
p53 protein after their transduction with Ad-p53 but not with control
adenovirus. Stimulation of T cells with Ad-p53-transduced DCs resulted
in generation of CTLs specific for p53-derived peptide. These data
demonstrate that DCs transduced with the wild-type p53
gene were able to induce a specific antitumor immune response. This
offers a new promising approach to immunotherapy of cancer. |
---|---|
ISSN: | 1078-0432 1557-3265 |